التفاصيل البيبلوغرافية
| العنوان: |
Evaluation of prognostic variables in chronic lymphocytic leukemia and association with disease stage. |
| المؤلفون: |
Attia, Hanaa R.M., Ibrahim, Mona Hamed, El-Aziz, Shereen H. Abd, Abdelrahman, Amany H., Sobeih, Mohamed Emam, Hagag, Heba A.A., Yassa, Marianne E., Osman, Randa A., Rawi, Rasha, El-Dayem, Omnia Y. Abd, Elsharkawi, Nahla, Abdelfattah, Raafat, Hassan, Naglaa M. |
| المصدر: |
Molecular & Clinical Oncology; May2021, Vol. 14 Issue 5, pN.PAG-N.PAG, 1p |
| مصطلحات موضوعية: |
CHRONIC lymphocytic leukemia, CHRONIC leukemia, DISEASE progression, FLUORESCENCE in situ hybridization, PROGNOSIS, LYMPHOCYTE count |
| مستخلص: |
The aim of the present study was to investigate different biological prognostic markers to identify high-risk patients with chronic lymphocytic leukemia (CLL) with a higher tumor burden, in order to ensure appropriate management. A total of 81 Egyptian patients with CLL were enrolled in the present study, with 75 healthy subjects serving as the control group. The expression of CD49d, CD38 and ZAP-70 in CLL cells was assessed using flow cytometry. The fluorescence in situ hybridization technique was employed to evaluate TP53 (del17p), ataxia-telangiectasia (del11q) and 13q14 (del13q14) genes and the presence of trisomy 12. The serological markers β2 microglobulin (B2M) and sCD23 were measured by ELISA. The CD49d gene was highly expressed in 25.9% and cytogenetic aberrations were observed in 66.6% of all recruited CLL patients. The patients were categorized according to the Binet staging system and a significant increase in the expression of sCD23, CD49d and ZAP-70 was detected in group C (P=0.008, 0.034 and 0.017, respectively) when compared to groups A and B. CD49d+ patients exhibited significantly higher expression of CD38 (P=0.002) and trisomy 12 (P=0.015) and lower expression of del13q14 (P=0.001). Patients who were CD49d+ with B2M>3.5 µg/ml exhibited higher total leukocyte count (P=0.048), higher absolute lymphocyte count (P=0.036), higher expression of CD38 (P=0.002) and trisomy 12 (P=0.034) and lower expression of del13q14 (P=0.002). Therefore, sCD23, CD49d and ZAP-70 may be considered as an optimal prognostic marker combination to be evaluated in the early stages of CLL and throughout disease management. Integrating both serological markers and CD49d expression by flow cytometry may add to the prognostic value of each marker alone and help identify high-risk patients with a higher tumor burden. [ABSTRACT FROM AUTHOR] |
|
Copyright of Molecular & Clinical Oncology is the property of Spandidos Publications UK Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder